Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Cash & Current Investments (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Cash & Current Investments for 8 consecutive years, with $540.7 million as the latest value for Q1 2026.

  • Quarterly Cash & Current Investments fell 1.63% to $540.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $540.7 million through Feb 2026, down 1.63% year-over-year, with the annual reading at $592.9 million for FY2025, 2.73% down from the prior year.
  • Cash & Current Investments for Q1 2026 was $540.7 million at Nurix Therapeutics, down from $592.9 million in the prior quarter.
  • The five-year high for Cash & Current Investments was $609.6 million in Q4 2024, with the low at $244.0 million in Q1 2024.
  • Average Cash & Current Investments over 5 years is $391.8 million, with a median of $344.5 million recorded in 2022.
  • The sharpest move saw Cash & Current Investments dropped 24.86% in 2023, then soared 125.29% in 2025.
  • Over 5 years, Cash & Current Investments stood at $309.1 million in 2022, then decreased by 6.87% to $287.9 million in 2023, then soared by 111.73% to $609.6 million in 2024, then fell by 2.73% to $592.9 million in 2025, then dropped by 8.81% to $540.7 million in 2026.
  • According to Business Quant data, Cash & Current Investments over the past three periods came in at $540.7 million, $592.9 million, and $428.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.